Syntara shows encouraging first signals it can impact the path to Parkinson's
Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...
Market Cap $6.338M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| PPY | Ann: Appendix 4C - quarterly | 23/04/18 | 13 | 574 | |||
|
|||||||
| PPY | Ann: Response to ASX Query | 28/03/18 | 2 | 327 | |||
|
|||||||
| PPY | Ann: Papyrus Egypt Business Project Update - 6 March 2018 | 15/03/18 | 16 | 2.6K | |||
|
|||||||
| PPY | Ann: Response to ASX Query | 05/03/18 | 0 | 142 | |||
|
|||||||
| PPY | Ann: Half Year Accounts | 28/02/18 | 0 | 95 | |||
|
|||||||
See All Discussions
ASX News